Entheon Biomedical Corp.CSE: ENBI.X

Entheon Announces Continuance into British Columbia

· Issued by Entheon Biomedical Corp. via Newsfile

Summary by 6ix AI

Entheon Biomedical Corp., a biotechnology research and development company interested in treating addiction and substance use disorders, has continued out of federal Canadian jurisdiction under the Canada Business Corporations Act into British Columbia's jurisdiction under the Business Corporations Act (British Columbia).

Key details

  • Shareholders approved the continuance, meaning the transfer of the company's legal home, at the annual general and special meeting of shareholders held on September 29, 2026.
  • As part of the continuance, the company replaced its articles and bylaws with a new notice of articles and articles under the British Columbia law.
  • The CUSIP and ISIN numbers (security identification codes) and the stock symbol for the company's common shares remain unchanged.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/entheon-announces-continuance-into-british-columbia

Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has continued out of the jurisdiction of Canada under the Canada Business Corporations Act into the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia) (the "BCBCA"). Shareholders approved the continuance at the Company's annual general and special meeting of shareholders held on September 29, 2026.

In connection with the continuance, the Company has replaced its articles and bylaws with new notice of articles and articles, respectively, under the BCBCA. The CUSIP / ISIN numbers for the Company's common shares and the stock symbol for the Company's common shares remain unchanged.

ABOUT ENTHEON BIOMEDICAL CORP.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,

Timothy Ko, CEO and Director

For more information, please contact the Company at:
Entheon Biomedical Corp.
Timothy Ko, CEO
1 (604) 562-3932
[email protected]
https://entheonbiomedical.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/318177

Source: Entheon Biomedical Corp.

View original source (Newsfile)Entheon Biomedical Corp. on 6ix

Earlier from Entheon Biomedical

All Entheon Biomedical news releases